X

 
News

BeiGene News

See all News

  • January 13, 2021
    China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer

    China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer

    Read More
  • January 11, 2021
    BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab

    BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab

    Read More
  • January 11, 2021
    Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology

    Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology

    Read More
  • January 7, 2021
    BeiGene to Present at the J.P. Morgan 39th Annual Healthcare Conference

    BeiGene to Present at the J.P. Morgan 39th Annual Healthcare Conference

    Read More
  • December 27, 2020
    BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL)

    BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL)

    Read More
  • December 7, 2020
    BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

    BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

    Read More
  • BeiGene Facts
  • 2010Founded
  • NASDAQ: BGNE  
    HKEX: 06160    Listings
  • 8Internally Developed
    Clinical Candidates
  • 6Marketed
    Products
    in China
  • 1Approved
    Product
    in the U.S.
  • 5200+Global Team
story
 
BeiGene Co-Founders, John V. Oyler and Xiaodong Wang, Ph.D.

2010

  • BeiGene was founded as a research and development company
BeiGene R&D Center

2011

  • Established the first R&D center in Beijing
  • Initiated PARP and RAF discovery programs
Immuno-oncology Therapies

2012

  • Initiated PD-1 and BTK discovery programs 
Clinical development in Australia

2013

  • Began clinical development of lifirafenib in Australia
Clinical Researcher

2014

  • Began clinical development of pamiparib and zanubrutinib in Australia
BeiGene opens first US office

2015

  • Began clinical development in China
  • Expanded into the U.S. with the first office established in Cambridge, MA
First China biotech to go public on the Nasdaq

2016

  • Became the first Chinese-born biotech to go public on Nasdaq with a $182 million IPO
  • Completed construction of the Suzhou small molecule manufacturing facility
Collaboration with Celgene

2017

  • Initiated the first global Phase 3 registrational trial of zanubrutinib
  • Entered global strategic immuno-oncology collaboration with Celgene on tislelizumab
  • Absorbed Celgene’s commercial operation in China
BeiGene expands global operations

2018

  • Established first European office in Switzerland
  • Completed dual primary listing on Hong Kong Stock Exchange with a $902 million IPO
  • Expanded into Europe with opening of the Basel office
  • Secured National Reimbursement in China for both Revlimid® and Vidaza®
Established research institute

2019

  • Received first FDA approval for BRUKINSA® (zanubrutinib)
  • Received first approval for tislelizumab in China
  • Entered a global strategic collaboration with Amgen
  • Completed the initial phase of BeiGene Guangzhou Bio-Manufacturing Base
  • Established BeiGene Suzhou Research Institute
Clinical development

2020

  • Received first approvals for BRUKINSA® in China
  • Received additional approvals for tislelizumab in China
  • Completed a registered direct offering of approx. $2.07 billion
  • Submitted the first new drug application for pamiparib in China

Our Story

Breaking Boundaries From the Beginning

From our start in Beijing with a handful of scientists and developers, to today, with a global team, a rich pipeline, strong partnerships, and commercial products. We have accomplished so much in a short time, and yet there is so much still to do.

Our Story

Partnering

Partnerships that Extend Around the Globe

BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships.

Partners

ZymeworksBioAtla LogoLeapSeagen_LogoAmbrx LogoMirati LogoMEI logoAmgen logoEUSA LogoAssembly Bio LogoChi-Med LogoBio-Thera LogoSinglomics Logostandtx

Our Patients

Our Commitment to Patients

At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.

Patients

Careers
 

Careers

Join Our
Team

We’re looking for highly motivated colleagues who can collaborate with us as we build a company that will have a lasting impact on the global fight against cancer.

Careers